Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is regarded as the most aggressive lymphoma worldwide.[@b1-cmar-11-2739],[@b2-cmar-11-2739] As early-stage DLBCL is hard to be diagnosed, DLBCL patients present poor prognosis.[@b3-cmar-11-2739],[@b4-cmar-11-2739] It is reported that 30%--40% of DLBCL patients might be refractory or relapse, even if they received a better therapeutic response to the first-line chemo-immunotherapy.[@b5-cmar-11-2739] Currently, the molecular mechanism of DLBCL formation and development remains unclear. Therefore, identifying the biomarkers associated with DLBCL has become more urgent.

miRNA is a kind of sn-cRNA that regulates gene expression at the translational and post-transcriptional levels.[@b6-cmar-11-2739],[@b7-cmar-11-2739] Current reports indicate that miRNA plays a key role in tumor formation and development by regulating cell apoptosis, proliferation, invasion and migration.[@b8-cmar-11-2739],[@b9-cmar-11-2739] miR-101 is a highly conserved miRNA, which is located in chromosome1p31.3 and 9p24.1.[@b10-cmar-11-2739] miR-101, as a tumor-suppressive miRNA, is lowly expressed in several cancer types, such as gastric cancer,[@b11-cmar-11-2739] hepatocellular carcinoma,[@b12-cmar-11-2739] melanoma[@b13-cmar-11-2739] and esophageal cancer.[@b14-cmar-11-2739] Moreover, miR-101 is involved in cell apoptosis, proliferation, migration and invasion.[@b14-cmar-11-2739]--[@b17-cmar-11-2739] However, the expression and biological functions of miR-101 in DLBCL are unknown.

In this study, the expression and biological functions of miR-101 were investigated in DLBCL. The potential molecular mechanism of miR-101 in cell apoptosis and proliferation was explored.

Methods
=======

Tissue sample collection and preparation
----------------------------------------

This study enrolled 30 lymph node samples from patients diagnosed with DLBCL and 30 individuals with normal lymph nodes as controls (NC). All samples were obtained from the Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, People's Republic of China, between July 2015 and December 2017. No patient received preoperative radiotherapy or chemotherapy before surgery. Samples were snap-frozen and stored in liquid nitrogen. All DLBCL diagnoses were confirmed by the pathologist on the basis of morphology and immunophenotypic findings. Clinicopathological features including age, gender, tumor size, extra-nodal status, B symptoms, lactate dehydrogenase (LDH), clinical stage and International Prognostic Index (IPI) score were collected from medical records and pathology reports. This study was conducted in accordance with the Declaration of Helsinki and supported by the Research Ethics Committee of Zhangzhou Affiliated Hospital of Fujian Medical University. All participants signed the informed consents.

Cell culture and transfection
-----------------------------

The OCL-LY7, OCL-LY8 and OCL-LY10 cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). All cells were cultured in RPMI-1640 containing 12% FBS (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) at 37°C in a humidified chamber supplemented with 5% CO~2~. Cell transfection was performed according to the manufacturer's protocol. OCL-LY8 cells were selected for the down-regulation and up-regulation experiment by transferring miR-101 siRNA/mimics (GenePharma, Suzhou, People's Republic of China), using Lipofectamine RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.). Scramble siRNA served as a control. The siRNA sequence for KDM1A was 5′-GAGGAAGAGGAAAUGGCUG-3′.

qRT-PCR
-------

Total RNA was extracted from tissue and cell specimens using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer's protocol. The detection of qRT-PCR was performed by using SYBR green qPCR assay (Takara, People's Republic of China). The primers of miR-101 and U6 were purchased from Riobio Biotech Corporation (Guangzhou, People's Republic of China). The primers of KDM1A were 5′-CTGATGCAGGCCATCAAGT-3′ (forward) and 5′-TCTCCAGGAAATGCATTGGT-3′ (reverse). The primers of GAPDH were 5′-TGGTGGACCTCATGGCCTAC-3′ (forward) and 5′-CAGCAACTGAGGGCCTCTCT-3′ (reverse). PCR reaction condition was as follow: 95°C for 15 minutes, followed by 40 cycles of 94°C for 15 seconds, 60°C for 30 seconds and 70°C for 30 seconds. Relative expression level was compared by the 2^−∆∆CT^ method.

Western blotting
----------------

Western blotting was used to detect KDM1A protein expression in OCL-LY8 cells. At 48 hours following transfection, total protein was extracted from cell specimens using lysis buffer containing 1% phenylmethanesulfonyl fluoride. Protein concentration was measured by bicinchoninic acid kit. Then, 50 µg protein specimens were separated by 10% SDS-PAGE and electrophoresed onto polyvinylidene difluoride membranes membranes. The membranes were blocked with 5% non-skim milk at room temperature for 2 hours, and incubated with rabbit monoclonal antibodies against KDM1A (1:1,000, Abcam USA, Cambridge, MA, USA) and GAPDH (1:2,000, Abcam USA) at 4°C overnight. HRP-conjugated secondary antibody (1:1,000, OriGene Technologies, Inc., Beijing, People's Republic of China) was used to incubate the membranes for 30 minutes at room temperature. Finally, signals were detected by the enhanced chemiluminescence kit (BestBio, Shanghai, People's Republic of China) for 3--5 minutes at room temperature.

Flow cytometric analysis
------------------------

At 48 hours following transfection, 2×10^6^ single cells were harvested with PBS and fixed in 70% ethanol overnight. Next day, cells were washed with PBS and incubated in propidium iodide (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and Annexin V-FITC (BestBio) at 37°C for 15 minutes. Cell apoptosis was evaluated using a BD FACSCanto II analyzer with Mac G4 Computer Workstation and Cell Quest Softwares (BD Biosciences, San Jose, CA, USA). Three independent experiments were repeated.

MTT assay for cell proliferation
--------------------------------

At 24 hours following transfection, 2×10^3^ single cells were cultured in 96-well plates at 37°C in 5% CO~2~. Plates were incubated with MTT reagents (5 mg/mL, 20 µL) for 4 hours. Then, dimethyl sulfoxide (150 µL) was used to stop the reaction and the OD was measured at 490 using a microplate reader. The experiment was followed for 5 days and repeated three times.

Statistical analysis
--------------------

All data are presented as the mean ± SD, and analyzed using SPSS 19.0 software (IBM Corporation, Armonk, NY, USA). The difference between the two groups was analyzed by independent samples *t* test. All tests were two-sided and *P*\<0.05 was considered to indicate a statistically significant difference.

Results
=======

miR-101 expression levels in DLBCL and correlation with clinicopathological features
------------------------------------------------------------------------------------

To evaluate the role of miR-101 in DLBCL, the expression levels of miR-101 were examined in DLBCL and normal lymph node tissues using qRT-PCR. As shown in [Figure 1A](#f1-cmar-11-2739){ref-type="fig"}, the expression levels of miR-101 were significantly reduced in DLBCL tissues compared with those in normal controls (*P*\<0.001). Then, the expression levels of miR-101 were also detected in DLBCL cell lines. Results show that the expression levels of miR-101 in DLBCL cell lines were also significantly reduced compared with the average levels of miR-101 in normal lymph node tissues ([Figure 1B](#f1-cmar-11-2739){ref-type="fig"}). These data indicated that miR-101 down-regulation was associated with the formation of DLBCL.

To further investigate the clinical significance of miR-101 in DLBCL, the correlation between miR-101 expression and clinicopathological features was analyzed. The median value of miR-101 expression in DLBCL tissues was regarded as the cutoff, and then miR-101 expression was divided into high-expression and low-expression. As shown in [Table 1](#t1-cmar-11-2739){ref-type="table"}, miR-101 low expression was positively associated with tumor size (*P*=0.034), clinical stage (*P*=0.013) and IPI scores (*P*=0.026). Thus, these data indicated that miR-101 down-regulation might contribute to the progression of DLBCL.

miR-101 down-regulation regulates cell apoptosis and proliferation in DLBCL
---------------------------------------------------------------------------

Next, the OCL-LY8 cell line was selected to knock-down and up-regulate the expression of miR-101, respectively. As shown in [Figure 2A](#f2-cmar-11-2739){ref-type="fig"}, miR-101 expression was successfully knocked-down by transferring miR-101 siRNA (*P*\<0.001). After transfection with miR-101 mimics, miR-101 expression was significantly up-regulated (*P*\<0.001) compared with controls. MTT assays revealed that miR-101 down-regulation significantly promoted cell proliferation, while miR-101 up-regulation received a reverse effect ([Figure 2B](#f2-cmar-11-2739){ref-type="fig"}). Flow cytometric analysis revealed that miR-101 down-regulation significantly inhibited cell apoptosis, and miR-101 up-regulation received a reverse effect ([Figure 2C](#f2-cmar-11-2739){ref-type="fig"}).

KDM1A is the target of miR-101 to regulate cell proliferation and apoptosis
---------------------------------------------------------------------------

To investigate the mechanism of miR-101 in DLBCL, Tar-getScanHuman 7.1 was used to predict the targets of miR-101. The predicted consequential pairing of the target region of miR-101 was located at position 166--173 of KDM1A ([Figure 3A](#f3-cmar-11-2739){ref-type="fig"}), and KDM1A was predicted as the possible target of miR-101. To validate the prediction, KDM1A expression was detected in DLBCL and normal lymph node tissues by qRT-PCR. As shown in [Figure 3B](#f3-cmar-11-2739){ref-type="fig"}, KDM1A expression levels in DLBCL tissues were significantly higher compared with those in normal lymph node tissues (*P*\<0.001). KDM1A high-expression was significantly correlated with tumor size, extra-nodal status and IPI ([Table 2](#t2-cmar-11-2739){ref-type="table"}, *P*\<0.05). Moreover, KDM1A expression was adversely correlated with the expression of miR-101 (*R*=−0.577, *P*=0.004). When miR-101 expression was successfully down-regulated and up-regulated in OCL-LY8 cells, the mRNA and protein expression levels of KDM1A were detected. Results show that miR-101 down-regulation resulted in a significant increase in KDM1A mRNA level and miR-101 up-regulation reversed the effect ([Figure 3C](#f3-cmar-11-2739){ref-type="fig"}). Meanwhile, miR-101 down-regulation increased the expression of KDM1A protein, which was reversed by miR-101 up-regulation ([Figure 3D](#f3-cmar-11-2739){ref-type="fig"}). The expression of KDM1A was significantly knocked down in OCL-LY8 cells, while the change of miR-101 expression level wasn't observed compared with control ([Figure 4A](#f4-cmar-11-2739){ref-type="fig"}). These data indicated that KDM1A was the target of miR-101.

To investigate the role of KDM1A in cell proliferation and apoptosis, KDM1A siRNA and miR101 siRNA/mimics were co-transferred into OCL-LY8 cells, respectively. MTT assay showed that KDM1A down-regulation resulted in the inhibition of cell proliferation ([Figure 4B](#f4-cmar-11-2739){ref-type="fig"}). Moreover, KDM1A knock-down in miR-101-expressing cells partially enhanced the miR-101-induced inhibition of cell proliferation ([Figure 4B](#f4-cmar-11-2739){ref-type="fig"}) and promotion of cell apoptosis ([Figure 4C](#f4-cmar-11-2739){ref-type="fig"}). These data suggested that KDM1A was a functionally relevant target of the effect of miR-101 on cell proliferation and apoptosis.

Discussion
==========

DLBCL is an aggressive disease and is characterized by heterogeneous morphology, clinical presentations, molecular and genetic features.[@b17-cmar-11-2739],[@b18-cmar-11-2739] The pathogenesis of DLBCL is complicated, being involved in different genetic and epigenetic changes.[@b19-cmar-11-2739],[@b20-cmar-11-2739] Recently, miRNAs were reported to be associated with the formation and development of DLBCL.[@b6-cmar-11-2739],[@b7-cmar-11-2739] miR-101 is reported to be associated with tumor formation and plays key roles in cell apoptosis, proliferation, migration and invasion.[@b11-cmar-11-2739]--[@b17-cmar-11-2739] However, the role of miR-101 in DLBCL is unknown. Meanwhile, the effect of miR-101 on cell proliferation and apoptosis in DLBCL is unknown.

In this study, it was observed that miR-101 was down-regulated in DLBCL tissues compared with normal tissues. The same trend was recorded in DLBCL cell lines. In addition, miR-101 downregulation was correlated with clinical stage, tumor size and IPI scores. These data indicate that miR-101 downregulation might contribute to the formation and progression of DLBCL. Meanwhile, Chen et al[@b21-cmar-11-2739] reported that miR-101 was down-regulated in gallbladder carcinoma patients and correlated with tumor size, tumor invasion, lymph node metastasis, TNM stage and poor survival. Han et al[@b22-cmar-11-2739] miR-101 downregulation positively correlated with lymph node metastasis and poor prognosis in non-small-cell lung cancer. Thus, our data seem to be in line with the current findings that miR-101 down-regulation correlates with tumor formation and progression.

Then, the biological functions of miR-101 in DLBCL were further investigated. Our data revealed that miR-101 played a key role in regulating cell proliferation and apoptosis. miR-101 downregulation promoted cell proliferation and inhibited cell apoptosis, which further supported that miR-101 was a tumor suppressor in DLBCL. Studies had confirmed that the role of miRNAs in tumors relied on their downstream targets.[@b23-cmar-11-2739],[@b24-cmar-11-2739] So, TargetScanHuman was used to predict the candidate target of miR-101 and KDM1A was confirmed to be the specific target of miR-101. miR-101 directly regulated the expression of KDM1A. Currently, KDM1A is reported to be highly expressed in some types of tumor and KDM1A up-regulation was connected with tumor formation and progression.[@b25-cmar-11-2739]--[@b27-cmar-11-2739] However, the expression of KDM1A in DLBCL was unclear. Our data showed that KDM1A was highly expressed in DLBCL tissues compared with those in normal tissues, which was adversely correlated with the expression of miR-101. KDM1A knock-down in DLBCL cells significantly inhibited cell proliferation and promoted cell apoptosis. KDM1A siRNA attenuated the promoting effect of miR-101 down-regulation on DLBCL cell proliferation, while enhancing the suppressing effect of miR-101 up-regulation on DLBCL cell apoptosis. These data suggest that miR-101 negatively regulated KDM1A to affect cell proliferation and apoptosis. Moreover, Zhang et al[@b28-cmar-11-2739] reported that miR-101 inhibited cell proliferation and promoted apoptosis in endometrial cancer by regulating PI3K/Akt/mTOR. Lin et al[@b14-cmar-11-2739] reported that miR-101 suppressed cell proliferation and induced cell apoptosis by targeting EZH2 in esophageal cancer. Bao et al[@b29-cmar-11-2739] reported that miR-101 inhibited the proliferation and metastasis in gallbladder carcinoma by regulating the MAPK/Erk and Smad pathways.

In conclusion, this study is the first to report that miR-101 expression is down-regulated in DLBCL and correlates with tumor formation and progression. Moreover, miR-101 regulates cell proliferation and apoptosis by targeting KDM1A in DLBCL cells.
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![miR-101 had reduced expression levels in DLBCL.\
**Notes:** (**A**) miR-101 expression levels were measured in DLBCL and normal lymph node tissues by qRT-PCR. \*Compared with NC, *P*\<0.001. (**B**) miR-101 expression levels were measured in DLBCL cell lines by qRT-PCR. \*Compared with NC, *P*\<0.001.\
**Abbreviations:** DLBCL, diffuse large B cell lymphoma; NC, normal control.](cmar-11-2739Fig1){#f1-cmar-11-2739}

![miR-101 down-regulation regulated cell apoptosis and proliferation in DLBCL.\
**Notes:** (**A**) The down-regulation and up-regulation of miR-101 in OCL-LY8 cells were validated by qRT-PCR. \*Compared with control, *P*\<0.001. (**B**) MTT assay revealed that miR-101 regulated cell proliferation. (**C**) Flow cytometric analysis revealed that miR-101 regulated cell apoptosis.](cmar-11-2739Fig2){#f2-cmar-11-2739}

![KDM1A is the target of miR-101.\
**Notes:** (**A**) KDM1A was the predicted target of miR-101 by TargetScanHuman 7.1. (**B**) KDM1A was highly expressed in DLBCL tissues compared with those in normal tissues. \*Compared with NC, *P*\<0.001. (**C**) miR-101 negatively regulated the mRNA level of KDM1A. \*Compared with control, *P*\<0.001. (**D**) miR-101 negatively regulated the protein level of KDM1A.](cmar-11-2739Fig3){#f3-cmar-11-2739}

![miR-101 negatively regulated KDM1A to affect cell proliferation and apoptosis.\
**Notes:** (**A**) KDM1A down-regulation didn't affect the expression of miR-101. \*Compared with control, *P*\<0.001. (**B**) MTT assay shows that KDM1A down-regulation resulted in the inhibition of cell proliferation and partially enhanced the miR-101-induced inhibition of cell proliferation. (**C**) Flow cytometric analysis revealed that KDM1A down-regulation promoted cell apoptosis and partially enhanced the miR-101-induced promotion of cell apoptosis.](cmar-11-2739Fig4){#f4-cmar-11-2739}

###### 

The correlation between miR-101 expression and clinicopathological features was analyzed in DLBCL

  Clinicopathological features   N    miR-101   *P*-value   
  ------------------------------ ---- --------- ----------- -------
  Age (years)                                               0.458
   ≤58                           12   6         6           
   \>58                          18   6         12          
  Gender                                                    0.442
   Male                          19   9         10          
   Female                        11   3         8           
  Extra-nodal status                                        
   \<2                           5    4         1           0.128
   ≥2                            25   8         17          
  B symptoms                                                
   Absent                        10   5         5           0.461
   Present                       20   7         13          
  LDH                                                       
   \<300                         13   7         6           0.264
   ≥300                          17   5         12          
  Clinical stage                                            0.013
   I--II                         9    7         2           
   III--IV                       21   5         16          
  Tumor size (cm)                                           0.034
   ≤3                            8    6         2           
   \>3                           22   6         16          
  IPI score                                                 0.026
   0--2                          6    5         1           
   ≥3                            24   7         17          

**Abbreviations:** LDH, lactate dehydrogenase; IPI, International Prognostic Index.

###### 

The correlation between KDM1A expression and clinicopathological features was analyzed in DLBCL

  Clinicopathological features   N    KDM1A   *P*-value   
  ------------------------------ ---- ------- ----------- -------
  Age (years)                                             0.139
   ≤58                           12   6       6           
   \>58                          18   14      4           
  Gender                                                  0.246
   Male                          19   11      8           
   Female                        11   9       2           
  Tumor size (cm)                                         0.007
   ≤3                            8    2       6           
   \>3                           22   18      4           
  Stage                                                   0.222
   I--II                         9    5       5           
   III--IV                       21   16      5           
  Extra-nodal status                                      0.002
   \<2                           5    0       5           
   ≥2                            25   20      5           
  B symptoms                                              0.461
   Absent                        10   5       5           
   Present                       20   7       13          
  LDH                                                     0.056
   \<300 U/L                     13   6       7           
   ≥300 U/L                      17   14      3           
  IPI score                                               0.009
   0--2                          6    1       5           
   ≥3                            24   19      5           

**Abbreviations:** LDH, lactate dehydrogenase; IPI, International Prognostic Index.
